Editas Medicine, Inc. (EDIT) Ownership
EDIT ownership summary
as of October 18, 2026- Institutions
- 79.4% of shares outstanding
- Insiders
- 0.18% of shares outstanding
- Shares outstanding
- 153.6M
- Float
- 115.5M shares available to trade
- Short interest
- 24.21% 37.1M shares short
- Days to cover
- 12.47 short interest up 23.8% vs prior month
- Institutions 79.40%
- Insiders 0.18%
- Other investors 20.42%
EDIT top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | TCG Crossover Management, LLC | 7.23% | 11.1M | $26.1M | +11.1M (0.0%) | June 30, 2026 |
| 2 | BlackRock Inc | 6.90% | 10.6M | $24.9M | +1.3M (+14.3%) | June 30, 2026 |
| 3 | COMMODORE CAPITAL LP | 5.79% | 8.9M | $20.9M | +8.9M (0.0%) | June 30, 2026 |
| 4 | RA Capital Management, LLC | 5.79% | 8.9M | $20.9M | +8.9M (0.0%) | June 30, 2026 |
| 5 | ADAR1 Capital Management LLC | 5.79% | 8.9M | $20.9M | +8.9M (0.0%) | June 30, 2026 |
| 6 | Vanguard Capital Management, LLC | 4.00% | 6.1M | $14.4M | +1.9M (+46.1%) | June 30, 2026 |
| 7 | Paradigm Biocapital Advisors LP | 3.64% | 5.6M | $13.1M | +5.6M (0.0%) | June 30, 2026 |
| 8 | Opaleye Management Inc | 2.51% | 3.9M | $9.1M | +1.9M (+100.4%) | June 30, 2026 |
| 9 | Vanguard Portfolio Management, LLC | 2.34% | 3.6M | $8.5M | +449,769 (+14.3%) | June 30, 2026 |
| 10 | Woodline Partners LP | 2.32% | 3.6M | $8.4M | +3.6M (0.0%) | June 30, 2026 |
| 11 | Vivo Capital, LLC | 2.31% | 3.6M | $8.4M | +3.6M (0.0%) | June 30, 2026 |
| 12 | GordonMD Global Investments LP | 2.04% | 3.1M | $7.3M | +3.1M (0.0%) | June 30, 2026 |
| 13 | The Goldman Sachs Group Inc | 1.70% | 2.6M | $6.1M | +2.1M (+368.0%) | June 30, 2026 |
| 14 | Geode Capital Management, LLC | 1.67% | 2.6M | $6.0M | +257,283 (+11.1%) | June 30, 2026 |
| 15 | Renaissance Technologies Corp | 1.61% | 2.5M | $5.8M | −1.5M (−37.8%) | June 30, 2026 |
| 16 | Logos Global Management LP | 1.45% | 2.2M | $5.2M | +2.2M (0.0%) | June 30, 2026 |
| 17 | State Street Corp | 1.43% | 2.2M | $5.2M | +115,681 (+5.6%) | June 30, 2026 |
| 18 | Marshall Wace Asset Management Ltd | 1.33% | 2.0M | $4.8M | +1.8M (+868.7%) | June 30, 2026 |
| 19 | D. E. Shaw & Co LP | 1.24% | 1.9M | $4.5M | −42,891 (−2.2%) | June 30, 2026 |
| 20 | JPMorgan Chase & Co | 1.21% | 1.9M | $4.4M | −84,890 (−4.4%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 17 holders added 65.7M shares and 3 cut 1.6M.
EDIT top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 3.18% | 4.9M | $11.5M | — | August 31, 2026 |
| 2 | State Street® SPDR® S&P® Biotech ETF | 2.77% | 4.3M | $10.0M | −81,350 (−1.9%) | September 30, 2026 |
| 3 | iShares Russell 2000 ETF | 2.59% | 4.0M | $9.4M | −45,888 (−1.1%) | September 30, 2026 |
| 4 | Vanguard Strategic Equity Inv | 1.32% | 2.0M | $4.8M | +159,480 (+8.5%) | June 30, 2026 |
| 5 | iShares Russell 2000 Growth ETF | 0.85% | 1.3M | $3.1M | −1,655 (−0.1%) | September 30, 2026 |
| 6 | Fidelity Small Cap Index | 0.71% | 1.1M | $2.6M | +3,731 (+0.3%) | July 31, 2026 |
| 7 | iShares Biotechnology ETF | 0.70% | 1.1M | $2.5M | −8,184 (−0.8%) | September 30, 2026 |
| 8 | Selectra J. Lamarck Biotech A | 0.65% | 1.0M | $2.4M | — | September 30, 2026 |
| 9 | Schwab US Small-Cap ETF™ | 0.45% | 696K | $1.6M | +468 (+0.1%) | September 30, 2026 |
| 10 | JPM Thmtcs Gentc Thrps C2 dist USD | 0.42% | 649K | $1.5M | +7,277 (+1.1%) | August 31, 2026 |
| 11 | Vanguard Russell 2000 ETF | 0.38% | 576K | $1.4M | +14,545 (+2.6%) | August 31, 2026 |
| 12 | Fidelity Extended Market Index | 0.34% | 520K | $1.2M | −2,793 (−0.5%) | August 31, 2026 |
| 13 | iShares Micro-Cap ETF | 0.32% | 494K | $1.2M | −3,406 (−0.7%) | September 30, 2026 |
| 14 | Vanguard Health Care ETF | 0.28% | 435K | $1.0M | −30,275 (−6.5%) | August 31, 2026 |
| 15 | Vanguard Strategic Small-Cap Equity Inv | 0.27% | 415K | $975,957 | — | June 30, 2026 |
| 16 | BSF Systematic US Eq Abs Ret A2 USD | 0.27% | 407K | $956,701 | +90,583 (+28.6%) | December 31, 2025 |
| 17 | JPMorgan US Small Company L | 0.19% | 286K | $671,151 | +7,386 (+2.7%) | August 31, 2026 |
| 18 | JPMorgan Small Cap Value I | 0.18% | 272K | $640,060 | — | August 31, 2026 |
| 19 | BlackRock Advantage Small Cap Gr Instl | 0.18% | 270K | $633,915 | — | August 31, 2026 |
| 20 | Schwab Small Cap Index | 0.16% | 244K | $572,747 | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
EDIT insider transactions
latest 11| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-03 | Amy Parison | Sell | $2.02 | 474 | $957 |
| 2026-03-03 | Gilmore Neil O'neill | Sell | $2.02 | 5,394 | $10,896 |
| 2026-03-03 | Linda Burkly | Sell | $2.02 | 749 | $1,513 |
| 2025-12-03 | Amy Parison | Sell | $2.15 | 461 | $991 |
| 2025-12-03 | Gilmore Neil O'neill | Sell | $2.15 | 5,603 | $12,046 |
| 2025-12-03 | Linda Burkly | Sell | $2.15 | 713 | $1,533 |
| 2025-08-07 | Amy Parison | Sell | $2.58 | 679 | $1,752 |
| 2025-07-31 | Linda Burkly | Sell | $2.49 | 5,121 | $12,751 |
| 2025-06-03 | Amy Parison | Sell | $1.72 | 446 | $767 |
| 2025-06-03 | Gilmore Neil O'neill | Sell | $1.72 | 15,192 | $26,130 |
| 2025-06-03 | Linda Burkly | Sell | $1.72 | 726 | $1,249 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
EDIT shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns EDIT
Institutional investors own 79.4% of Editas Medicine's shares and insiders 0.18%. The largest holder is TCG Crossover Management, LLC with 7.23% of the shares (11.1M), as of June 30, 2026. Among the top 20 institutions, 17 added shares and 3 reduced their stake in the latest filings. Short interest is 24.21% of the float, or 12.47 days of average trading volume. The share count rose 2,097.4% since 2014.
Related: EDIT analyst forecast, EDIT key metrics. See the EDIT stock overview for the latest quote and news.
EDIT ownership FAQ
Who owns the most Editas Medicine stock?
The largest shareholders of Editas Medicine are TCG Crossover Management, LLC (7.23%), BlackRock Inc (6.90%), COMMODORE CAPITAL LP (5.79%), RA Capital Management, LLC (5.79%), ADAR1 Capital Management LLC (5.79%).
What percentage of Editas Medicine is owned by institutions?
Institutions hold 79.4% of Editas Medicine's shares outstanding; insiders hold 0.18%.
Which funds own Editas Medicine?
The largest fund holders of Editas Medicine are Vanguard MStar Total Stk Mkt Idx Invest (3.18%), State Street® SPDR® S&P® Biotech ETF (2.77%), iShares Russell 2000 ETF (2.59%), Vanguard Strategic Equity Inv (1.32%), iShares Russell 2000 Growth ETF (0.85%).
What is Editas Medicine's short interest?
37.1M shares of Editas Medicine were sold short, 24.21% of the float; at the average daily volume it would take 12.47 days to cover.
Are insiders buying or selling Editas Medicine?
Of the latest 11 reported insider transactions in Editas Medicine (since June 3, 2025), 0 were purchases and 11 were sales.
How many shares of Editas Medicine are outstanding?
Editas Medicine has 153.6M shares outstanding, of which 115.5M are in the public float.